|
[1]
|
GBD 2015 Risk Factors Collaborators (2016) Global, Regional, and National Comparative Risk Assessment of 79 Be-havioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks, 1990-2015: A Systematic Analy-sis for the Global Burden of Disease Study 2015. The Lancet, 388, 1659-1724. [Google Scholar] [CrossRef]
|
|
[2]
|
Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Mauro, M.J., O’dwyer, M.E. and Druker, B.J. (2001) ST1571, a Tyrosine Kinase Inhibitor for the Treatment of Chronic Myelogenous Leukemia: Validating the Promise of Molecularly Targeted Therapy. Cancer Chemotherapy and Pharmacology, 48, S77-S78. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Perazella, M.A. (2012) Onco-Nephrology: Renal Toxicities of Chemotherapeutic Agents. Clinical Journal of the American Society of Nephrology, 7, 1713-1721. [Google Scholar] [CrossRef]
|
|
[5]
|
Geng, Q., Shen, H., Zhu, W., et al. (2020) Safety and Efficacy of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous-Cell Carcinoma: A Prospective Cohort Study. On-coTargets and Therapy, 13, 11529-11535. [Google Scholar] [CrossRef]
|
|
[6]
|
Li, L., Kong, F., Zhang, L., et al. (2020) Apatinib, a Novel VEGFR-2 Tyrosine Kinase Inhibitor, for Relapsed and Refractory Nasopharyngeal Carcinoma: Data from an Open-Label, Sin-gle-Arm, Exploratory Study. Investigational New Drugs, 38, 1847-1853. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Izzedine, H., Escudier, B., Lhomme, C., et al. (2014) Kidney Diseases Associated with Anti-Vascular Endothelial Growth Factor (VEGF): An 8-Year Observational Study at a Single Center. Medicine (Baltimore), 93, 333-339. [Google Scholar] [CrossRef]
|
|
[8]
|
Vigneau, C., Lorcy, N., Dolley-Hitze, T., et al. (2014) All Anti-Vascular Endothelial Growth Factor Drugs Can Induce “Pre-Eclampsia-Like Syndrome”: A RARe Study. Neph-rology Dialysis Transplantation, 29, 325-332. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Carvalho, B., Lopes, R.G., Linhares, P., et al. (2020) Hypertension and Proteinuria as Clinical Biomarkers of Response to Bevacizumab in Glioblastoma Patients. Journal of Neuro-Oncology, 147, 109-116. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Khoja, L., Kumaran, G., Zee, Y.K., et al. (2014) Evaluation of Hypertension and Proteinuria as Markers of Efficacy in Antiangiogenic Therapy for Metastatic Colorectal Cancer. Jour-nal of Clinical Gastroenterology, 48, 430-434. [Google Scholar] [CrossRef]
|
|
[11]
|
Mourad, J.J., Des Guetz, G., Debbabi, H., et al. (2008) Blood Pressure Rise Following Angiogenesis Inhibition by Bevacizumab. A Crucial Role for Microcirculation. Annals of Oncology, 19, 927-934. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Liu, F., Hidru, T.H., Gao, R., et al. (2020) Cancer Patients with Po-tential Eligibility for Vascular Endothelial Growth Factor Antagonists Use Have an Increased Risk for Cardiovascular Diseases Comorbidities. Journal of Hypertension, 38, 426-433. [Google Scholar] [CrossRef]
|
|
[13]
|
Zhu, X., Wu, S., Dahut, W.L., et al. (2007) Risks of Pro-teinuria and Hypertension with Bevacizumab, an Antibody against Vascular Endothelial Growth Factor: Systematic Re-view and Meta-Analysis. American Journal of Kidney Diseases, 49, 186-193. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Van Dorst, D.C.H., Dobbin, S.J.H., Neves, K.B., et al. (2021) Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. Circulation Research, 128, 1040-1061. [Google Scholar] [CrossRef]
|
|
[15]
|
Azizi, M., Chedid, A. and Oudard, S. (2008) Home Blood-Pressure Monitoring in Patients Receiving Sunitinib. The New England Journal of Medicine, 358, 95-97. [Google Scholar] [CrossRef]
|
|
[16]
|
Corr, B.R., Breed, C., Sheeder, J., et al. (2016) Bevacizumab Induced Hypertension in Gynecologic Cancer: Does It Resolve after Completion of Therapy? Gynecologic Oncology Reports, 17, 65-68. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Izzedine, H., Rixe, O., Billemont, B., et al. (2007) Angiogenesis Inhibitor Therapies: Focus on Kidney Toxicity and Hypertension. American Journal of Kidney Diseases, 50, 203-218. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Aghajanian, C., Goff, B., Nycum, L.R., et al. (2015) Final Overall Survival and Safety Analysis of OCEANS, a Phase 3 Trial of Chemotherapy with or without Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovarian Cancer. Gynecologic Oncology, 139, 10-16. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Rapsomaniki, E., Timmis, A., George, J., et al. (2014) Blood Pressure and Incidence of Twelve Cardiovascular Diseases: Lifetime Risks, Healthy Life-Years Lost, and Age-Specific Associations in 1.25 Million People. The Lancet, 383, 1899-1911. [Google Scholar] [CrossRef]
|
|
[20]
|
Law, M.R., Morris, J.K. and Wald, N.J. (2009) Use of Blood Pressure Lowering Drugs in the Prevention of Cardiovascular Disease: Meta-Analysis of 147 Randomised Trials in the Context of Expectations from Prospective Epidemiological Studies. BMJ, 338, b1665. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Dobbin, S.J.H., Petrie, M.C., Myles, R.C., et al. (2021) Cardiotoxic Effects of Angiogenesis Inhibitors. Clinical Science (London), 135, 71-100. [Google Scholar] [CrossRef]
|
|
[22]
|
Mittal, K., Koon, H., Elson, P., et al. (2014) Dual VEGF/VEGFR Inhi-bition in Advanced Solid Malignancies: Clinical Effects and Pharmacodynamic Biomarkers. Cancer Biology & Therapy, 15, 975-981. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Rini, B.I., Garcia, J.A., Cooney, M.M., et al. (2010) Toxicity of Sunitinib plus Bevacizumab in Renal Cell Carcinoma. Journal of Clinical Oncology, 28, e284-e285. [Google Scholar] [CrossRef]
|
|
[24]
|
Usui, J., Glezerman, I.G., Salvatore, S.P., et al. (2014) Clinico-pathological Spectrum of Kidney Diseases in Cancer Patients Treated with Vascular Endothelial Growth Factor Inhibitors: A Report of 5 Cases and Review of Literature. Human Pathology, 45, 1918-1927. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Walter, R.B., Joerger, M. and Pestalozzi, B.C. (2002) Gem-citabine-Associated Hemolytic-Uremic Syndrome. American Journal of Kidney Diseases, 40, E16. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Weitz, I.C. (2018) Thrombotic Microangiopathy in Cancer. Throm-bosis Research, 164, S103-S105. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Moake, J.L. (2002) Thrombotic Microangiopathies. The New England Journal of Medicine, 347, 589-600. [Google Scholar] [CrossRef]
|
|
[28]
|
Renaghan, A.D., Jaimes, E.A., Malyszko, J., et al. (2020) Acute Kid-ney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation. Clinical Journal of the American Society of Nephrology, 15, 289-297. [Google Scholar] [CrossRef]
|
|
[29]
|
Pfister, F., Amann, K., Daniel, C., et al. (2018) Characteristic Mor-phological Changes in Anti-VEGF Therapy-Induced Glomerular Microangiopathy. Histopathology, 73, 990-1001. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Izzedine, H., Mangier, M., Ory, V., et al. (2014) Expression Patterns of RelA and c-mip Are Associated with Different Glomerular Diseases Following Anti-VEGF Therapy. Kidney Interna-tional, 85, 457-470. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Forsythe, J.A., Jiang, B.H., Iyer, N.V., et al. (1996) Activation of Vascu-lar Endothelial Growth Factor Gene Transcription by Hypoxia-Inducible Factor 1. Molecular and Cellular Biology, 16, 4604-4613. [Google Scholar] [CrossRef]
|
|
[32]
|
Ning, L., Suleiman, H.Y. and Miner, J.H. (2020) Synaptopodin Is Dispensable for Normal Podocyte Homeostasis but Is Protective in the Context of Acute Podocyte Injury. Journal of the American Society of Nephrology, 31, 2815-2832. [Google Scholar] [CrossRef]
|
|
[33]
|
Ning, L., Suleiman, H.Y. and Miner, J.H. (2021) Synaptopodin Deficiency Exacerbates Kidney Disease in a Mouse Model of Alport Syndrome. The American Journal of Physiolo-gy—Renal Physiology, 321, F12-F25. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Quintanilha, J.C.F., Liu, Y., Etheridge, A.S., et al. (2022) Plasma Levels of Angiopoietin-2, VEGF-A, and VCAM-1 as Markers of Bevacizumab-Induced Hypertension: CALGB 80303 and 90401 (Alliance). Angiogenesis, 25, 47-55. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Izzedine, H., Massard, C., Spano, J.P., et al. (2010) VEGF Sig-nalling Inhibition-Induced Proteinuria: Mechanisms, Significance and Management. European Journal of Cancer, 46, 439-448. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Kamba, T., Tam, B.Y., Hashizume, H., et al. (2006) VEGF-Dependent Plasticity of Fenestrated Capillaries in the Normal Adult Microvasculature. The American Journal of Physiology-Heart and Circulatory Physiology, 290, H560-H576. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Porta, C., Cosmai, L., Gallieni, M., et al. (2015) Renal Effects of Targeted Anticancer Therapies. Nature Reviews Nephrology, 11, 354-370. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Mirabito Colafella, K.M., Neves, K.B., Montezano, A.C., et al. (2020) Selective ETA vs. Dual ETA/B Receptor Blockade for the Prevention of Sunitinib-Induced Hypertension and Albuminu-ria in WKY Rats. Cardiovascular Research, 116, 1779-1790. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Gurevich, F. and Perazella, M.A. (2009) Renal Effects of Anti-Angiogenesis Therapy: Update for the Internist. The American Journal of Medicine, 122, 322-328. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Zou, A.P. and Cowley, A.W. (1999) Role of Nitric Oxide in the Control of Renal Function and Salt Sensitivity. Current Hypertension Reports, 1, 178-186. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Robinson, E.S., Khankin, E.V., Karumanchi, S.A., et al. (2010) Hypertension Induced by Vascular Endothelial Growth Factor Signaling Pathway Inhibition: Mechanisms and Potential Use as a Biomarker. Seminars in Nephrology, 30, 591-601. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Hsu, P.Y., Mammadova, A., Benkirane-Jessel, N., et al. (2021) Updates on Anticancer Therapy-Mediated Vascular Toxicity and New Horizons in Therapeutic Strategies. Fron-tiers in Cardiovascular Medicine, 8, Article ID: 694711. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
González-Pacheco, F.R., Deudero, J.J., Castellanos, M.C., et al. (2006) Mechanisms of Endothelial Response to Oxidative Aggression: Protective Role of Autologous VEGF and Induc-tion of VEGFR2 by H2O2. The American Journal of Physiology-Heart and Circulatory Physiology, 291, H1395-H1401. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
张菊, 谢席胜. TSP-1-CD47激活氧化应激与肾脏损伤[J]. 中国中西医结合肾病杂志, 2016, 17(5): 458-460.
|
|
[45]
|
Plummer, C., Michael, A., Shaikh, G., et al. (2019) Expert Rec-ommendations on the Management of Hypertension in Patients with Ovarian and Cervical Cancer Receiving Bevaci-zumab in the UK. British Journal of Cancer, 121, 109-116. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Versmissen, J., Mirabito Colafella, K.M., Koolen, S.L.W., et al. (2019) Vascular Cardio-Oncology: Vascular Endothelial Growth Factor Inhibitors and Hypertension. Cardiovascular Research, 115, 904-914. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Izzedine, H. and Perazella, M.A. (2015) Thrombotic Microangiopathy, Cancer, and Cancer Drugs. American Journal of Kidney Diseases, 66, 857-868. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Fremeaux-Bacchi, V., Dragon-Durey, M.A., Blouin, J., et al. (2004) Complement Factor I: A Susceptibility Gene for Atypical Haemolytic Uraemic Syndrome. Journal of Medical Genetics, 41, e84. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Favaloro, E.J., Pasalic, L., Henry, B., et al. (2021) Laboratory Test-ing for ADAMTS13: Utility for TTP Diagnosis/Exclusion and Beyond. American Journal of Hematology, 96, 1049-1055. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Mannucci, P.M., Karimi, M., Mosalaei, A., et al. (2003) Pa-tients with Localized and Disseminated Tumors Have Reduced But Measurable Levels of ADAMTS-13 (von Willebrand Factor Cleaving Protease). Haematologica, 88, 454-458.
|
|
[51]
|
Rosner, M.H., Jhaveri, K.D., Mcmahon, B.A., et al. (2021) Onconephrology: The Intersections between the Kidney and Cancer. CA: A Cancer Journal for Clinicians, 71, 47-77. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Kwiatkowska, E., Domański, L., Dziedziejko, V., et al. (2021) The Mechanism of Drug Nephrotoxicity and the Methods for Preventing Kidney Damage. International Journal of Molecular Sciences, 22, 6109. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Kanbayashi, Y., Ishikawa, T., Tabuchi, Y., et al. (2020) Predictive Fac-tors for the Development of Proteinuria in Cancer Patients Treated with Bevacizumab, Ramucirumab, and Aflibercept: A Single-Institution Retrospective Analysis. Scientific Reports, 10, Article No. 2011. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Maitland, M.L., Bakris, G.L., Black, H.R., et al. (2010) Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors. Journal of the National Cancer Institute, 102, 596-604. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Zamorano, J.L., Lancellotti, P., Rodriguez Muñoz, D., et al. (2016) 2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed under the Auspices of the ESC Com-mittee for Practice Guidelines: The Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Soci-ety of Cardiology (ESC). European Heart Journal, 37, 2768-2801. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
James, M.T., Grams, M.E., Woodward, M., et al. (2015) A Me-ta-Analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension with Acute Kidney Injury. American Journal of Kidney Diseases, 66, 602-612. [Google Scholar] [CrossRef] [PubMed]
|